Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis (Pro-Muco)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00750932
Recruitment Status : Completed
First Posted : September 11, 2008
Last Update Posted : February 27, 2017
Information provided by (Responsible Party):
University Hospital, Tours

September 10, 2008
September 11, 2008
February 27, 2017
January 2008
January 2012   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00750932 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis
Study of the Biodistribution of PMN Serine Proteases in Sputum of Patients Affected by Cystic Fibrosis: Towards New Anti-inflammatory Therapies

The purpose of the proposed project is to characterize the neutrophile proteases which participate in the chronic inflammatory phenomenon associated with the cystic fibrosis and which are responsible for the degradation of the lung tissue.

The respiratory failure which results from it is one of main causes of the fatal evolution of this pathology but the anti-inflammatory therapies based on the use of antiproteases targeting specifically the soluble elastase did not end, until now, in the hoped results.

The identification of the other noxious targets is a crucial element to give new orientations to the anti-inflammatory strategies based on the administration of antiproteases which remain a promising way.

Not Provided
Observational Model: Case-Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Whole blood Sputum
Non-Probability Sample
Adults and children with cystic fibrosis
Cystic Fibrosis
Not Provided
  • T
  • M
    Minor with cystic fibrosis
  • A
    Adult with cystic fibrosis
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2012
January 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Man /woman older than 18 years (for adult and group)
  • Child aged 6 to 18 years (for child group)
  • Suffering from cystic fibrosis in stable condition, ie not having presented thrust acute attack of the broncho-pulmonary or hospitalization for treatment of his illness during the previous 2 weeks

Exclusion Criteria:

  • colonized by Burkholderia cepacia ou Stenotrophomonas maltophilia
  • non smoker (control group)
  • Without history or respiratory respiratory disease known (control group)
  • Antibiotic treatment and / or anti-inflammatory drug (NSAID or corticosteroids) in the 2 weeks prior to the inclusion in the study (control group)
Sexes Eligible for Study: All
6 Years and older   (Child, Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
AOHP07-PD Pro-Muco
N° ID RCB:2007-A00511-52
CPP: 2007-R17
Not Provided
Not Provided
University Hospital, Tours
University Hospital, Tours
Not Provided
Principal Investigator: Patrice DIOT, PHD Tours Hospital
University Hospital, Tours
February 2017